FDG and FLT PET-CT for malignant tumors

(F-18)FDG(F-18)FLT (3'-Deoxy-3'-(18F)fluorothymidine)PET/CT for malignant tumors - FDG and FLT PET-CT for malignant tumors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180014

Enrollment

120

Registered

2018-08-20

Start date

2018-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumors

Interventions

Use of (F-18) FLT (3'-Deoxy-3'-[F-18]fluorothymidine)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Assured for (F-18) FDG PET/CT, greater than or equal to 20 year of age with written informed consent

Exclusion criteria

Exclusion criteria: BS greater than or equal to 200mg/dl, pregnancy or suspected , without infromed consent

Design outcomes

Primary

Measure	Time frame
Accuracy of (F-18) FLT PET/CT	—

Contacts

Public ContactJYUNICHI TATEISHI

Tokyo Medical and Dental University

tcymrad@tmd.ac.jp+81-358035311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026